

## Schedule

<i>Name and Strength</i>	<i>Form</i>	<i>Name and Address of Manufacturer</i>	<i>Proprietary Name (if any)</i>
Naproxen 250 mg, 500 mg	Tablet	Apotex Inc., Canada	
Piretanide 6 mg	Tablet	Hoechst AG, Federal Republic of Germany	Arelix
Lorazepam 1 mg, 2.5 mg	Tablet	Glaxo NZ Ltd., Palmerston North	
Atenolol 50 mg, 100 mg	Tablet	Apotex Inc., Canada	
Naproxen 250 mg, 500 mg	Tablet	Clonmel Chemicals Co. Ltd., Ireland	
Terazosin hydrochloride 1 mg, 2 mg, 5 mg, 10 mg	Tablet	Abbott Laboratories Aust Pty Ltd., Australia, Abbott Laboratories Ltd., USA and United Kingdom	Hytrin
Sulindac 100 mg, 150 mg, 200 mg	Tablet	Novopharm Ltd., Canada	Saldac
Calcium carbonate 500 mg	Tablet	Norcliff Thayer Inc., USA	Tums
Fluoxetine hydrochloride 60 mg	Capsule	Eli Lilly International Corporation USA or Elanco S.A. Republic of Ireland	Prozac 60
Idoxuridine 0.5%	Cream	Milpharma Pty Ltd., Australia	Virasolve
Lignocaine hydrochloride 2%			
Benzalkonium chloride 0.5%			
Zinc oxide 200 mg/1 g	Impregnated gauze	Aco Lakemedel, Sweden	Acoband
Water for injection 2 ml, 5 ml, 10 ml, 20 ml	Ampoule	The Boots Company (Australia) Pty Ltd., Australia	
Sodium bicarbonate 8.4% w/v 10 ml	Ampoule	The Boots Company (Australia) Pty Ltd., Australia	
Adrenaline acid tartrate 1 mg/ml	Ampoule	The Boots Company (Australia) Pty Ltd., Australia	
Potassium dihydrogen phosphate 0.54 g in 10 ml	Ampoule	David Bull Laboratories Pty Ltd., Australia	
Dipotassium hydrogen phosphate 1.83 g in 10 ml	Ampoule	David Bull Laboratories Pty Ltd., Australia	
Potassium dihydrogen phosphate 1.35 g in 10 ml	Ampoule	David Bull Laboratories Pty Ltd., Australia	
Triamcinolone acetonide 40 mg/ml	Suspension for injection	Steris Laboratories Inc., USA	
Vancomycin hydrochloride 500 mg	Powder in vial	Lederle Parentals Inc., USA	Vancoled
Dextrose hydrous 1.5%, 2.5%, 4.25% w/v with sodium chloride 0.538% w/v, sodium lactate 0.448% w/v, calcium chloride 0.257% w/v, magnesium chloride 0.00508% w/v	Solution	Delmed Inc., USA	Peritosteril

Dated this 25th day of January 1989.

DAVID CAYGILL, Minister of Health.

go1831

## Inland Revenue

### Income Tax Act 1976

#### Determination E4: Persons Not Required to Comply with Section 104A of the Income Tax Act 1976

1. *Reference*—This determination is made pursuant to section 104A (5) of the Income Tax Act 1976. It determines the extent to which persons are not required to comply with section 104A of the Income Tax Act 1976, in respect of the income year commencing on the 1st day of April 1988.

2. *Interpretation*—In this determination, unless the context otherwise requires—

Expressions used have the same meanings as in section 2 and section 104A of the Income Tax Act 1976:

Every reference to an income year shall, where a person furnishes a return of income under section 15 of the Income Tax Act 1976, for an accounting year ending with a day other

than the 31st day of March, be deemed to be a reference to the accounting year corresponding with that income year and, in every such case, this determination shall, with necessary modifications, apply accordingly.

“Audit fees” in relation to a person and an income year means fees payable by the person to a qualified person in relation to the preparation of a report relating to any financial statement relating to the person and the income year for financial reporting purposes:

“Balance date”, in relation to a person and an income year, means the last day of the person’s income year:

“Expenditure” means accrual expenditure:

“Expiry date”, in relation to any expenditure incurred in an income year, means—

- (a) Where the expenditure relates to payment for services, the date by which it is reasonably expected that performance of the service will be completed;
- (b) Where the expenditure relates to payment for, or in relation to, a chose in action—
  - (i) For a definite period, the last day of that period: